Published in Cell on January 25, 2002
Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol (2007) 10.49
Cre-lox-regulated conditional RNA interference from transgenes. Proc Natl Acad Sci U S A (2004) 9.33
Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes Dev (2003) 8.27
An oncogenomics-based in vivo RNAi screen identifies tumor suppressors in liver cancer. Cell (2008) 5.47
Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells. Science (2009) 5.31
Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase. Nat Protoc (2009) 4.50
CRISPR-mediated direct mutation of cancer genes in the mouse liver. Nature (2014) 3.28
Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models. Nat Biotechnol (2010) 3.15
Murine models to evaluate novel and conventional therapeutic strategies for cancer. Am J Pathol (2007) 3.03
Mouse models of human AML accurately predict chemotherapy response. Genes Dev (2009) 2.75
Mouse models of advanced spontaneous metastasis for experimental therapeutics. Nat Rev Cancer (2011) 2.42
Suppression of Rev3, the catalytic subunit of Pol{zeta}, sensitizes drug-resistant lung tumors to chemotherapy. Proc Natl Acad Sci U S A (2010) 1.95
Somatic integration of an oncogene-harboring Sleeping Beauty transposon models liver tumor development in the mouse. Proc Natl Acad Sci U S A (2005) 1.72
Cancer gene discovery in hepatocellular carcinoma. J Hepatol (2010) 1.68
Rapid tolerization of virus-activated tumor-specific CD8+ T cells in prostate tumors of TRAMP mice. Proc Natl Acad Sci U S A (2008) 1.60
Hyperactivation of Ha-ras oncogene, but not Ink4a/Arf deficiency, triggers bladder tumorigenesis. J Clin Invest (2007) 1.59
Institutional shared resources and translational cancer research. J Transl Med (2009) 1.41
A quantitative and multiplexed approach to uncover the fitness landscape of tumor suppression in vivo. Nat Methods (2017) 1.40
Antitumor activity of the investigational proteasome inhibitor MLN9708 in mouse models of B-cell and plasma cell malignancies. Clin Cancer Res (2011) 1.32
Strategies for high-resolution imaging of epithelial ovarian cancer by laparoscopic nonlinear microscopy. Transl Oncol (2010) 1.31
Perturbation of Rb, p53, and Brca1 or Brca2 cooperate in inducing metastatic serous epithelial ovarian cancer. Cancer Res (2012) 1.30
Preclinical development of molecular-targeted agents for cancer. Nat Rev Clin Oncol (2010) 1.27
Physico-mechanical aspects of extracellular matrix influences on tumorigenic behaviors. Semin Cancer Biol (2010) 1.21
Genetically engineered mouse models in cancer research. Adv Cancer Res (2010) 1.18
MYC Inactivation Elicits Oncogene Addiction through Both Tumor Cell-Intrinsic and Host-Dependent Mechanisms. Genes Cancer (2010) 1.18
Radiotherapy augments the immune response to prostate cancer in a time-dependent manner. Prostate (2008) 1.17
Predicting drug responsiveness in human cancers using genetically engineered mice. Clin Cancer Res (2013) 1.16
Establishment and genomic characterization of mouse xenografts of human primary prostate tumors. Am J Pathol (2010) 1.15
Timed somatic deletion of p53 in mice reveals age-associated differences in tumor progression. PLoS One (2009) 1.15
Integrating predictive biomarkers and classifiers into oncology clinical development programmes. Nat Rev Drug Discov (2011) 1.14
Generating somatic mosaicism with a Cre recombinase-microsatellite sequence transgene. Nat Methods (2008) 1.14
Assessing tumor progression factors by somatic gene transfer into a mouse model: Bcl-xL promotes islet tumor cell invasion. PLoS Biol (2007) 1.13
Toxicity modelling of Plk1-targeted therapies in genetically engineered mice and cultured primary mammalian cells. Nat Commun (2011) 1.12
Models of breast cancer: quo vadis, animal modeling? Breast Cancer Res (2003) 1.10
Regression of drug-resistant lung cancer by the combination of rosiglitazone and carboplatin. Clin Cancer Res (2008) 1.09
Malignancy-associated vessel tortuosity: a computer-assisted, MR angiographic study of choroid plexus carcinoma in genetically engineered mice. AJNR Am J Neuroradiol (2006) 1.08
Robust activation of the human but not mouse telomerase gene during the induction of pluripotency. FASEB J (2010) 1.07
Exosome in tumour microenvironment: overview of the crosstalk between normal and cancer cells. Biomed Res Int (2014) 1.01
Multicolor fluorescent intravital live microscopy (FILM) for surgical tumor resection in a mouse xenograft model. PLoS One (2009) 0.99
Preclinical Mouse Cancer Models: A Maze of Opportunities and Challenges. Cell (2015) 0.99
Orthotopic mouse models for the preclinical and translational study of targeted therapies against metastatic human thyroid carcinoma with BRAF(V600E) or wild-type BRAF. Oncogene (2013) 0.97
In vivo biomarkers for targeting colorectal neoplasms. Cancer Biomark (2008) 0.94
The untapped potential of genetically engineered mouse models in chemoprevention research: opportunities and challenges. Cancer Prev Res (Phila) (2008) 0.92
Comparison of expression profiles of metastatic versus primary mammary tumors in MMTV-Wnt-1 and MMTV-Neu transgenic mice. Neoplasia (2008) 0.91
Optochemogenetics (OCG) allows more precise control of genetic engineering in mice with CreER regulators. Bioconjug Chem (2012) 0.90
Targeted molecular imaging in oncology: focus on radiation therapy. Semin Radiat Oncol (2008) 0.89
Precision cancer mouse models through genome editing with CRISPR-Cas9. Genome Med (2015) 0.89
Mouse models for cancer stem cell research. Toxicol Pathol (2009) 0.86
Competing views on cancer. J Biosci (2014) 0.86
Fatigue and sleep during cancer and chemotherapy: translational rodent models. Comp Med (2008) 0.85
Overview of human primary tumorgraft models: comparisons with traditional oncology preclinical models and the clinical relevance and utility of primary tumorgrafts in basic and translational oncology research. Curr Protoc Pharmacol (2012) 0.85
Transcriptional profile of Rous Sarcoma Virus transformed chicken embryo fibroblasts reveals new signaling targets of viral-src. Virology (2007) 0.84
Live-cell imaging of tumor proteolysis: impact of cellular and non-cellular microenvironment. Biochim Biophys Acta (2011) 0.84
Forward genetic screens in mice uncover mediators and suppressors of metastatic reactivation. Proc Natl Acad Sci U S A (2014) 0.82
Temporally and spatially controllable gene expression and knockout in mouse urothelium. Am J Physiol Renal Physiol (2010) 0.82
Effects of hypoxia on heterotypic macrophage interactions. Cell Cycle (2007) 0.82
Order, disorder, death: lessons from a superorganism. Adv Cancer Res (2006) 0.81
Use of mouse models to study the role of tissue factor in tumor biology. Semin Thromb Hemost (2008) 0.81
Necdin, a p53-target gene, is an inhibitor of p53-mediated growth arrest. PLoS One (2012) 0.81
Aspirin prolongs survival and reduces the number of Foxp3+ regulatory T cells in a genetically engineered mouse model of pancreatic cancer. Langenbecks Arch Surg (2013) 0.80
Tetracycline regulated systems in functional oncogenomics. Transl Oncogenomics (2007) 0.79
Drosophila as an emerging model to study metastasis. Genome Biol (2004) 0.79
3D viability imaging of tumor phantoms treated with single-walled carbon nanohorns and photothermal therapy. Nanotechnology (2013) 0.78
Pathologic progression of mammary carcinomas in a C3(1)/SV40 T/t-antigen transgenic rat model of human triple-negative and Her2-positive breast cancer. Transgenic Res (2010) 0.78
New stochastic carcinogenesis model with covariates: an approach involving intracellular barrier mechanisms. Math Biosci (2011) 0.78
Evaluating the number of stages in development of squamous cell and adenocarcinomas across cancer sites using human population-based cancer modeling. PLoS One (2012) 0.78
Quantification of Tumor Burden in a Genetically Engineered Mouse Model of Lung Cancer by Micro-CT and Automated Analysis. Transl Oncol (2015) 0.78
A medaka model of cancer allowing direct observation of transplanted tumor cells in vivo at a cellular-level resolution. Proc Natl Acad Sci U S A (2009) 0.78
Optimizing mouse models for precision cancer prevention. Nat Rev Cancer (2016) 0.77
Malignant transformation in a defined genetic background: proteome changes displayed by 2D-PAGE. Mol Cancer (2010) 0.77
GI GEMs: genetically engineered mouse models of gastrointestinal disease. Gastroenterology (2010) 0.77
An algorithm for molecular dissection of tumor progression. J Math Biol (2004) 0.77
In Vivo Loss of Function Screening Reveals Carbonic Anhydrase IX as a Key Modulator of Tumor Initiating Potential in Primary Pancreatic Tumors. Neoplasia (2015) 0.77
Inducing stable reversion to achieve cancer control. Nat Rev Cancer (2016) 0.76
Mammary-Stem-Cell-Based Somatic Mouse Models Reveal Breast Cancer Drivers Causing Cell Fate Dysregulation. Cell Rep (2016) 0.76
Systems biology approaches to decoding the genome of liver cancer. Cancer Res Treat (2011) 0.76
Natural history of tumor growth and immune modulation in common spontaneous murine mammary tumor models. Breast Cancer Res Treat (2014) 0.76
Animal Models of Chemical Carcinogenesis: Driving Breakthroughs in Cancer Research for 100 Years. Cold Spring Harb Protoc (2015) 0.76
Sleeping Beauty transposon system for genetic etiological research and gene therapy of cancers. Cancer Biol Ther (2015) 0.76
Radiation promotes colorectal cancer initiation and progression by inducing senescence-associated inflammatory responses. Oncogene (2015) 0.75
Effectors and potential targets selectively upregulated in human KRAS-mutant lung adenocarcinomas. Sci Rep (2016) 0.75
Decoding human liver cancer signatures. Gastrointest Cancer Res (2008) 0.75
Development of zebrafish medulloblastoma-like PNET model by TALEN-mediated somatic gene inactivation. Oncotarget (2017) 0.75
MicroRNA expression profiles classify human cancers. Nature (2005) 69.12
Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals. Nature (2009) 35.48
Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nat Genet (2007) 15.46
Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell (2003) 15.43
Identification of bronchioalveolar stem cells in normal lung and lung cancer. Cell (2005) 15.06
Restoration of p53 function leads to tumour regression in vivo. Nature (2007) 12.62
Targeted deletion reveals essential and overlapping functions of the miR-17 through 92 family of miRNA clusters. Cell (2008) 12.29
A large intergenic noncoding RNA induced by p53 mediates global gene repression in the p53 response. Cell (2010) 12.27
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature (2009) 11.46
An oncogenic KRAS2 expression signature identified by cross-species gene-expression analysis. Nat Genet (2004) 10.92
Cre-lox-regulated conditional RNA interference from transgenes. Proc Natl Acad Sci U S A (2004) 9.33
Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell (2004) 8.48
Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects. Cancer Cell (2004) 8.16
MicroRNAs and cancer: short RNAs go a long way. Cell (2009) 7.25
Suppression of non-small cell lung tumor development by the let-7 microRNA family. Proc Natl Acad Sci U S A (2008) 6.89
Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell (2009) 6.55
Acute mutation of retinoblastoma gene function is sufficient for cell cycle re-entry. Nature (2003) 6.01
The differential effects of mutant p53 alleles on advanced murine lung cancer. Cancer Res (2005) 5.93
Dicer1 functions as a haploinsufficient tumor suppressor. Genes Dev (2009) 5.21
Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon. Nat Genet (2008) 5.07
Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer. Nat Med (2004) 4.98
Requirement for NF-kappaB signalling in a mouse model of lung adenocarcinoma. Nature (2009) 4.93
AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell (2009) 4.71
p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature (2002) 4.56
Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase. Nat Protoc (2009) 4.50
Tumor predisposition in mice mutant for p63 and p73: evidence for broader tumor suppressor functions for the p53 family. Cancer Cell (2005) 4.14
A spatially and temporally restricted mouse model of soft tissue sarcoma. Nat Med (2007) 3.96
Expression of tumour-specific antigens underlies cancer immunoediting. Nature (2012) 3.89
Growth-inhibitory and tumor- suppressive functions of p53 depend on its repression of CD44 expression. Cell (2008) 3.75
Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease. J Clin Invest (2004) 3.47
Classification of proliferative pulmonary lesions of the mouse: recommendations of the mouse models of human cancers consortium. Cancer Res (2004) 3.43
Context-dependent transformation of adult pancreatic cells by oncogenic K-Ras. Cancer Cell (2009) 3.37
Treating metastatic cancer with nanotechnology. Nat Rev Cancer (2011) 3.30
Suppression of lung adenocarcinoma progression by Nkx2-1. Nature (2011) 3.27
Mechanism for the learning deficits in a mouse model of neurofibromatosis type 1. Nature (2002) 3.05
Stage-specific sensitivity to p53 restoration during lung cancer progression. Nature (2010) 3.03
Autophagy suppresses progression of K-ras-induced lung tumors to oncocytomas and maintains lipid homeostasis. Genes Dev (2013) 2.90
Single-molecule transcript counting of stem-cell markers in the mouse intestine. Nat Cell Biol (2011) 2.72
PKM2 isoform-specific deletion reveals a differential requirement for pyruvate kinase in tumor cells. Cell (2013) 2.38
Nuclear factor I/B is an oncogene in small cell lung cancer. Genes Dev (2011) 2.29
Targeted point mutations of p53 lead to dominant-negative inhibition of wild-type p53 function. Proc Natl Acad Sci U S A (2002) 2.24
Merlin, the product of the Nf2 tumor suppressor gene, is an inhibitor of the p21-activated kinase, Pak1. Mol Cell (2003) 2.23
Cell type-specific effects of Rb deletion in the murine retina. Genes Dev (2004) 2.18
p53 controls radiation-induced gastrointestinal syndrome in mice independent of apoptosis. Science (2009) 2.11
Nkx2-1 represses a latent gastric differentiation program in lung adenocarcinoma. Mol Cell (2013) 2.05
Proliferation and tumorigenesis of a murine sarcoma cell line in the absence of DICER1. Cancer Cell (2012) 2.04
Suppression of Rev3, the catalytic subunit of Pol{zeta}, sensitizes drug-resistant lung tumors to chemotherapy. Proc Natl Acad Sci U S A (2010) 1.95
Chronic cisplatin treatment promotes enhanced damage repair and tumor progression in a mouse model of lung cancer. Genes Dev (2010) 1.95
Use of gene expression profiling to direct in vivo molecular imaging of lung cancer. Proc Natl Acad Sci U S A (2005) 1.91
Endogenous T cell responses to antigens expressed in lung adenocarcinomas delay malignant tumor progression. Cancer Cell (2011) 1.89
HIF-2alpha deletion promotes Kras-driven lung tumor development. Proc Natl Acad Sci U S A (2010) 1.86
The related retinoblastoma (pRb) and p130 proteins cooperate to regulate homeostasis in the intestinal epithelium. J Biol Chem (2005) 1.85
Merlin phosphorylation by p21-activated kinase 2 and effects of phosphorylation on merlin localization. J Biol Chem (2002) 1.82
Sprouty-2 regulates oncogenic K-ras in lung development and tumorigenesis. Genes Dev (2007) 1.81
ROS fusion tyrosine kinase activates a SH2 domain-containing phosphatase-2/phosphatidylinositol 3-kinase/mammalian target of rapamycin signaling axis to form glioblastoma in mice. Cancer Res (2006) 1.80
Requirement for Rac1 in a K-ras induced lung cancer in the mouse. Cancer Res (2007) 1.80
A functional switch from lung cancer resistance to susceptibility at the Pas1 locus in Kras2LA2 mice. Nat Genet (2006) 1.79
Chimeric mouse tumor models reveal differences in pathway activation between ERBB family- and KRAS-dependent lung adenocarcinomas. Nat Biotechnol (2009) 1.76
Characterizing deformability and surface friction of cancer cells. Proc Natl Acad Sci U S A (2013) 1.72
Progesterone receptor expression in neurofibromas. Cancer Res (2003) 1.72
Mist1-KrasG12D knock-in mice develop mixed differentiation metastatic exocrine pancreatic carcinoma and hepatocellular carcinoma. Cancer Res (2006) 1.69
Targeted deletion reveals an essential function for the telomere length regulator Trf1. Mol Cell Biol (2003) 1.69
The Rb tumor suppressor is required for stress erythropoiesis. EMBO J (2004) 1.68
Selective killing of K-ras mutant cancer cells by small molecule inducers of oxidative stress. Proc Natl Acad Sci U S A (2011) 1.68
The comparative pathology of genetically engineered mouse models for neuroendocrine carcinomas of the lung. J Thorac Oncol (2015) 1.68
Optimality in the development of intestinal crypts. Cell (2012) 1.67
A reversible gene-targeting strategy identifies synthetic lethal interactions between MK2 and p53 in the DNA damage response in vivo. Cell Rep (2013) 1.67
Dynamic regulation of the Ras pathway via proteolysis of the NF1 tumor suppressor. Genes Dev (2003) 1.64
Defective apoptosis and B-cell lymphomas in mice with p53 point mutation at Ser 23. EMBO J (2004) 1.63
An induced Ets repressor complex regulates growth arrest during terminal macrophage differentiation. Cell (2002) 1.63
Activation of the p53-dependent G1 checkpoint response in mouse embryo fibroblasts depends on the specific DNA damage inducer. Oncogene (2004) 1.61
Hematopoiesis and leukemogenesis in mice expressing oncogenic NrasG12D from the endogenous locus. Blood (2010) 1.60
Susceptibility to astrocytoma in mice mutant for Nf1 and Trp53 is linked to chromosome 11 and subject to epigenetic effects. Proc Natl Acad Sci U S A (2004) 1.55
Imaging primary lung cancers in mice to study radiation biology. Int J Radiat Oncol Biol Phys (2010) 1.48
Response and resistance to NF-κB inhibitors in mouse models of lung adenocarcinoma. Cancer Discov (2011) 1.46
Murine bilateral retinoblastoma exhibiting rapid-onset, metastatic progression and N-myc gene amplification. EMBO J (2007) 1.46
Increased sensitivity to UV radiation in mice with a p53 point mutation at Ser389. Mol Cell Biol (2004) 1.44
Recapitulation of the effects of the human papillomavirus type 16 E7 oncogene on mouse epithelium by somatic Rb deletion and detection of pRb-independent effects of E7 in vivo. Mol Cell Biol (2003) 1.43
p63 and p73 transcriptionally regulate genes involved in DNA repair. PLoS Genet (2009) 1.41
Cross species genomic analysis identifies a mouse model as undifferentiated pleomorphic sarcoma/malignant fibrous histiocytoma. PLoS One (2009) 1.40
Comparison of gene expression and DNA copy number changes in a murine model of lung cancer. Genes Chromosomes Cancer (2006) 1.36
RB signaling prevents replication-dependent DNA double-strand breaks following genotoxic insult. Nucleic Acids Res (2004) 1.33
A physical sciences network characterization of non-tumorigenic and metastatic cells. Sci Rep (2013) 1.33
Mammalian RNAi: a practical guide. Biotechniques (2005) 1.32
ARF is not required for apoptosis in Rb mutant mouse embryos. Curr Biol (2002) 1.30
Tissue-specific p19Arf regulation dictates the response to oncogenic K-ras. Proc Natl Acad Sci U S A (2010) 1.28
Caspase-2-mediated cleavage of Mdm2 creates a p53-induced positive feedback loop. Mol Cell (2011) 1.27
Mice expressing a mammary gland-specific R270H mutation in the p53 tumor suppressor gene mimic human breast cancer development. Cancer Res (2005) 1.26
Regulated expression of a tumor-associated antigen reveals multiple levels of T-cell tolerance in a mouse model of lung cancer. Cancer Res (2008) 1.25
Cellular transformation by a FERM domain mutant of the Nf2 tumor suppressor gene. Oncogene (2002) 1.23
Cyclooxygenase-1 is overexpressed in multiple genetically engineered mouse models of epithelial ovarian cancer. Cancer Res (2006) 1.22
Uncoupling cancer mutations reveals critical timing of p53 loss in sarcomagenesis. Cancer Res (2011) 1.21
The Nf2 tumor suppressor regulates cell-cell adhesion during tissue fusion. Proc Natl Acad Sci U S A (2007) 1.17
Impaired SHP2-mediated extracellular signal-regulated kinase activation contributes to gefitinib sensitivity of lung cancer cells with epidermal growth factor receptor-activating mutations. Cancer Res (2010) 1.16
ARF mutation accelerates pituitary tumor development in Rb+/- mice. Proc Natl Acad Sci U S A (2002) 1.15
Technologically advanced cancer modeling in mice. Curr Opin Genet Dev (2002) 1.14
p53 constrains progression to anaplastic thyroid carcinoma in a Braf-mutant mouse model of papillary thyroid cancer. Proc Natl Acad Sci U S A (2014) 1.14
Dominant role of oncogene dosage and absence of tumor suppressor activity in Nras-driven hematopoietic transformation. Cancer Discov (2013) 1.13
Requirement of c-Jun NH(2)-terminal kinase for Ras-initiated tumor formation. Mol Cell Biol (2011) 1.12
Multiple response elements and differential p53 binding control Perp expression during apoptosis. Mol Cancer Res (2003) 1.11